Norwood Abbey, MIT sign license agreement for needle-free injections

By Lisa Kerner

Erie, Pa., March 14 - Norwood Abbey Ltd. said it has entered into a commercial-phase license agreement with Massachusetts Institute of Technology to develop a needle-free drug delivery system and a microneedle drug delivery system for use in human and veterinary medicine.

Under the agreement, Norwood has an exclusive worldwide license over all technological developments emerging from the contracted works programs with MIT, according to a company news release.

Norwood said the agreement covers 10 patent families covering one issued U.S. patent and about 50 applications.

MIT will earn a royalty from revenues generated by the commercialized products.

The human use product is a small reusable handheld device about the size of an electric toothbrush.

MIT has conducted preliminary trials of the human use hand-held prototype device, as well as the first live animal studies using a prototype needle-free device.

Norwood is a Melbourne, Australia-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.